---
schema_version: "secwatch.filing_event.v1"
accession: "0001005286-23-000108"
form_type: "8-K"
ticker: "LFCR"
cik: "0001005286"
company_name: "LIFECORE BIOMEDICAL, INC. DE"
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T00:53:20.676581+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lifecore Biomedical Q4 revenue up 12% to $31.5M; net loss widens to $33.8M on debt refinancing

## Summary
- Q4 consolidated revenue $31.5M (+12.2% YoY); gross profit $8.4M (-33.9% YoY); net loss from continuing ops $33.8M vs $1.0M loss prior year.
- Full year FY2023 revenue $103.3M (-7.2% YoY); net loss from continuing ops $69.0M; adjusted EBITDA $5.8M vs $22.9M prior year.
- Q4 net loss includes $23.8M loss on debt refinancing and $6.8M restructuring/legal charges; adjusted EBITDA fell to $3.7M from $9.1M.
- CEO notes final divestitures of Curation Foods, expanded supply agreement with Alcon, and new customer projects added in Q4.
- Capacity expansions: multi-use fillers to double filling capacity to ~45M units; HA fermentation moving to 24/7 to boost capacity up to 50% by June 2024.

## SEC filing metadata
- accession: 0001005286-23-000108
- form_type: 8-K
- ticker: LFCR
- cik: 0001005286
- company_name: LIFECORE BIOMEDICAL, INC. DE
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/lndc-20230831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001005286-23-000108
- JSON: https://secwatch.observer/filing/0001005286-23-000108.json
- Plain text: https://secwatch.observer/filing/0001005286-23-000108.txt

## Key facts
- Earnings Releases
  LIFECORE BIOMEDICAL, INC. DE reported the fourth quarter and full year of fiscal 2023 ended May 28, 2023 results: revenue $31.5 million, net income Net loss from continuing operations of $33.8 million.
  - Period: the fourth quarter and full year of fiscal 2023 ended May 28, 2023
  - Revenue: $31.5 million
  - Net income: Net loss from continuing operations of $33.8 million
  - Result: reported results
  source text: fiscal 2024 second quarter and to a greater degree in the second half of the fiscal year." LIFECORE FISCAL FOURTH QUARTER 2023 FINANCIAL HIGHLIGHTS: • Consolidated revenues of $31.5 million, an increase of 12.2% year-over-year. • Consolidated gross profit of $8.4 million, a decrease of $4.3 million, or 33.9% year-over-year • Consolidated net loss from continuing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528623000108/0001005286-23-000108-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.